At a time when most Indian drug makers are launching generics to monetise patent expiries in the US, Glenmark has chosen to walk a road less travelled. The company has chosen a strategy to capture

A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will